Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
CymaBay Therapeutics, Inc.
| Metric | CymaBay Therapeutics, Inc. Healthcare |
|---|---|
| Quality Score | 35 / 100 |
| Revenue (latest) | $31M |
| Net income (latest) | −$105M |
| Operating margin | −327.2% |
| Net margin | −339.1% |
| Return on equity | −36.1% |
| Return on assets | −24.2% |
| Return on capital (ROCE) | −25.6% |
| Debt / equity | 0.49× |
| Revenue growth (YoY) | −96.9% |
| Altman Z″ (distress) | -1.22 |
| Accruals / assets | −7.6% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.